Biosion
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building D 3-1 Zhongdan Unit South Longs...Phone Number
(302) 257-5085Website
www.biosion.comRevenue
$6.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Biosion
Biosion is a global clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive global biologics development experience, and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H3 antibody discovery platform, SynAb synergistic antibody platform, SynTracer HT-endocytosis platform, and Flexibody bispecific platform and external source of innovation. The lead asset BSI-045B (anti-TSLP mAb) is currently in a global phase I clinical trial, with multiple assets expected to reach the clinic in 2022. Biosion has operations in the US, Australia and China. The mission of Biosion is to discover and develop innovative biologics through the synergy of great science, cutting-edge technologies and superior craftmanship for patients worldwide. BiosioRead more
Biosion Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biosion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Biosion launches new products
Congratulate Masked Content for being promoted to Masked Content at Biosion
Check if Biosion has recently received funding, and reach out quickly before it becomes old news!
Click to see if Biosion had a recent Job posting/layoffs
Check out if Biosion is spiking on competitors!
Biosion, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Biosion has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Biosion recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Biosion
Compare insights from companies similar to Biosion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biosion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biosion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biosion.
Biosion Tech Stack
A closer look at the technologies used by Biosion
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Partnership
Project
Partnership, Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Furqan Ahmed has been named Vice President & Head of Business Development. Previously, Ahmed served as Vice President, Business Development for Immunome.
Left Company
Executive Move
New Hire
Executive Move
Biosion News & Media
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated Trial (IIT) evaluatBiosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"),...Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment of Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise...Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Biosion
Sign Up For FreeTo access detailed company insights
Biosion is a global clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive global biologics development experience, and built an oncology and auto-immune focused pipeline of innovativ... Read More
